Intellia Therapeutics, Inc.

What does it do?

Intellia Therapeutics is a biotech company trying to cure diseases by editing the human genome — essentially fixing the typos in your DNA that cause illness. They use a technology called CRISPR/Cas9, which works like molecular scissors that can cut out or correct faulty genetic instructions inside your cells. Their lead drug candidate targets a rare, deadly disease called ATTR amyloidosis, where a misfolded protein builds up and damages the heart and nerves. Instead of managing symptoms forever, the idea is to go in once, fix the root cause, and potentially never need treatment again.

How does it make money?

Intellia is a clinical-stage company, meaning it does not yet sell a product to patients — so it currently earns almost no product revenue. Its $0.1 billion in annual revenue comes almost entirely from collaboration and licensing deals, primarily a long-running partnership with Regeneron Pharmaceuticals, which pays Intellia to co-develop certain therapies. The company is spending heavily — losing around $400 million per year — to fund clinical trials, research, and operations. Real revenue only arrives if and when the FDA approves a drug for sale.

Why do investors care?

The bull case is simple: if Intellia's lead drug, nexiguran ziclumeran (NTLA-2001), gets FDA approval, the company could go from zero product sales to hundreds of millions of dollars in revenue almost overnight. ATTR amyloidosis affects tens of thousands of patients in the U.S. alone, and a one-time cure would command a premium price. Beyond that, the CRISPR platform is modular — meaning the same delivery technology can be pointed at different genetic targets, building a pipeline from a single scientific foundation. Investors are essentially betting the platform works before the market fully prices it in.